Literature DB >> 12917264

X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus.

Minoru Satoh1, Akiei Mizutani, Krista M Behney, Yoshiki Kuroda, Jun Akaogi, Hideo Yoshida, Dina C Nacionales, Michito Hirakata, Nobutaka Ono, Westley H Reeves.   

Abstract

Murine lupus can occur spontaneously or be induced by hydrocarbons, such as pristane. Spontaneous disease in MRL and NZB/W F1 mice is suppressed by the xid (X-linked immunodeficiency) mutation, which greatly diminishes T cell-independent type 2 responses as well as the number of peritoneal B1 cells. The present study asked whether lupus induced by i.p. injection of pristane likewise is inhibited by the xid defect. Male CBA/N (xid) mice were refractory to the induction of autoantibodies by pristane, whereas 23% of pristane-treated male CBA/CaJ controls produced anti-nRNP/Sm, -Su and/or -OJ (isoleucyl tRNA synthetase) antibodies. Unexpectedly, 43% (12 of 28) of the xid mice spontaneously produced anti-nuclear antibodies that proved highly specific for the lupus antigen RNA helicase A (RHA). Strikingly, this specificity was absent in CBA/CaJ mice (none of 51). Moreover, pristane treatment suppressed the production of anti-RHA antibodies when administered prior to the onset of autoantibody production, but enhanced anti-RHA levels when given after the onset of autoantibody production, suggesting that pristane interferes with anti-RHA production at an early stage. Large amounts of IgG1 anti-RHA autoantibodies were detected in the sera of xid mice, whereas pristane-induced anti-nRNP/Sm and -Su autoantibodies were almost exclusively IgG2a. Cytokine production within the peritoneal cavity reflected the predominant isotypes: IL-12 and IFN-gamma predominated in pristane-treated mice, whereas IL-4 and IL-6 were more predominant in untreated xid mice. The spontaneous production of anti-RHA by xid mice and its suppression by pristane treatment at the level of autoantibody induction supports the idea that lupus autoantibodies may be generated through a variety of mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917264     DOI: 10.1093/intimm/dxg110

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

1.  DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells.

Authors:  Zhiqiang Zhang; Bin Yuan; Ning Lu; Valeria Facchinetti; Yong-Jun Liu
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

2.  Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalin.

Authors:  Rahul D Pawar; Beatrice Goilav; Yumin Xia; Haoyang Zhuang; Leal Herlitz; Westley H Reeves; Chaim Putterman
Journal:  Clin Immunol       Date:  2014-06-24       Impact factor: 3.969

3.  Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies.

Authors:  Claudia Azucena Palafox Sánchez; Minoru Satoh; Edward Kl Chan; Wendy C Carcamo; José Francisco Muñoz Valle; Gerardo Orozco Barocio; Edith Oregon Romero; Rosa Elena Navarro Hernández; Mario Salazar Páramo; Antonio Cabral Castañeda; Mónica Vázquez Del Mercado
Journal:  Arthritis Res Ther       Date:  2009-02-20       Impact factor: 5.156

4.  High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus.

Authors:  Monica Vázquez-Del Mercado; Claudia A Palafox-Sánchez; Jose F Muñoz-Valle; Gerardo Orozco-Barocio; Edith Oregon-Romero; Rosa E Navarro-Hernández; Mario Salazar-Páramo; Juan Armendariz-Borunda; Jorge I Gámez-Nava; Laura Gonzalez-Lopez; Jason Yf Chan; Edward Kl Chan; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2010-01-08       Impact factor: 5.156

5.  An antiviral response directed by PKR phosphorylation of the RNA helicase A.

Authors:  Anthony J Sadler; Olivier Latchoumanin; David Hawkes; Johnson Mak; Bryan R G Williams
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.